Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol
Autor: | Morten C. Moe, Rowan Thomas Faber, Øystein Kalsnes Jørstad |
---|---|
Rok vydání: | 2017 |
Předmět: |
Male
0301 basic medicine medicine.medical_specialty Time Factors Visual acuity genetic structures Bevacizumab Fundus Oculi Recombinant Fusion Proteins Visual Acuity Angiogenesis Inhibitors Treat and extend 03 medical and health sciences 0302 clinical medicine Ranibizumab Ophthalmology medicine Humans Macula Lutea Prospective Studies Fluorescein Angiography Prospective cohort study Treatment resistant Aged Aflibercept Drug Substitution business.industry General Medicine Macular degeneration medicine.disease eye diseases Receptors Vascular Endothelial Growth Factor Treatment Outcome 030104 developmental biology Intravitreal Injections Wet Macular Degeneration 030221 ophthalmology & optometry Female sense organs medicine.symptom business Tomography Optical Coherence Follow-Up Studies medicine.drug |
Zdroj: | Acta Ophthalmologica. 95:460-463 |
ISSN: | 1755-375X |
Popis: | Purpose To study the effects of converting to aflibercept in accordance with a treat and extend (T&E) strategy in eyes with treatment resistant exudative age-related macular degeneration (AMD). Methods Two-year prospective study of eyes with exudative AMD and persistent macular fluid despite monthly treatment with ranibizumab or bevacizumab. Eyes were converted to 2.0 mg aflibercept in accordance with a T&E protocol. Results Fifty eyes from 47 patients were included. At baseline, the mean central retinal thickness (CRT) was 273 μm and mean best-corrected visual acuity (BCVA) 0.25 logarithm of the minimal angle of resolution (logMAR). The mean number of aflibercept injections the first year was 9.2. After 1 year, there was a reduction in mean CRT to 228 μm (p |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |